临床与CT定量特征预测胰腺神经内分泌肿瘤患者肝转移:一项前瞻性/外部验证研究
该研究纳入病理确诊的胰腺神经内分泌肿瘤患者,训练组133例、前瞻性内部验证组22例、外部验证组28例,收集临床信息与定量CT特征,采用单因素和多因素logistic分析确定肝转移的独立预测因素,并以ROC曲线评估诊断效能。结果显示肿瘤标志物升高、最大径大于24.6 mm及动脉期绝对强化值≤51 HU为独立阳性预测因素,训练组AUC为0.852,前瞻性内部验证组AUC为0.883,外部验证组AUC为0.789。
要点
- 肿瘤标志物升高、最大径>24.6 mm、动脉期绝对强化值≤51 HU为肝转移独立阳性预测因素。
- 联合临床与定量CT特征预测肝转移训练组AUC 0.852,前瞻性内部验证组0.883,外部验证组0.789。
- 伴肝转移的胰腺神经内分泌肿瘤表现为直径更大、动脉/门脉肿瘤-实质强化比及绝对强化值更低。
核心结论
- 肿瘤标志物、最大径及动脉期绝对强化值是胰腺神经内分泌肿瘤肝转移的独立预测因素,联合临床与定量特征可获得较好的预测精度。
研究设计与样本
- 研究纳入病理确诊的胰腺神经内分泌肿瘤患者,训练组133例、前瞻性内部验证组22例、外部验证组28例,收集临床信息与定量CT特征,采用单因素及多因素logistic分析确定独立预测变量,并以ROC曲线评估诊断效能。
关键影像表现/征象
- 伴肝转移的胰腺神经内分泌肿瘤表现为直径显著更大、动脉/门脉肿瘤-实质强化比及动脉/门脉绝对强化值显著更低(p<0.05)。
诊断标准与关键数值
- 多因素分析显示肿瘤标志物高水平OR 5.32(95%CI 1.54-18.35)、最大径大于24.6 mm OR 7.46(95%CI 1.70-32.72)、动脉期绝对强化值≤51 HU OR 4.99(95%CI 0.93-26.95)为肝转移独立阳性预测因素。
临床应用与阅片要点
- 阅片时可关注胰腺神经内分泌肿瘤的最大径及动脉期绝对强化值,结合肿瘤标志物水平综合评估肝转移风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: We aimed to evaluate clinical characteristics and quantitative CT imaging features for the prediction of liver metastases (LMs) in patients with pancreatic neuroendocrine tumors (PNETs).
METHODS: Patients diagnosed with pathologically confirmed PNETs were included, 133 patients were in the training group, 22 patients in the prospective internal validation group, and 28 patients in the external validation group. Clinical information and quantitative features were collected. The independent variables for predicting LMs were confirmed through the implementation of univariate and multivariate logistic analyses. The diagnostic performance was evaluated by conducting receiver operating characteristic curves for predicting LMs in the training and validation groups.
RESULTS: PNETs with LMs demonstrated significantly larger diameter and lower arterial/portal tumor-parenchymal enhancement ratio, arterial/portal absolute enhancement value (AAE/PAE value) (p < 0.05). After multivariate analyses, A high level of tumor marker (odds ratio (OR): 5.32; 95% CI, 1.54-18.35), maximum diameter larger than 24.6 mm (OR: 7.46; 95% CI, 1.70-32.72), and AAE value ≤ 51 HU (OR: 4.99; 95% CI, 0.93-26.95) were independent positive predictors of LMs in patients with PNETs, with area under curve (AUC) of 0.852 (95%CI, 0.781-0.907). The AUCs for prospective internal and external validation groups were 0.883 (95% CI, 0.686-0.977) and 0.789 (95% CI, 0.602-0.916), respectively.
CONCLUSION: Tumor marker, maximum diameter and absolute enhancement value in arterial phase were independent predictors with good predictive performance for the prediction of LMs in patients with PNETs. Combining clinical and quantitative features may facilitate the attainment of good predictive precision in predicting LMs.
引用
- Pan Y, Chen HY, Chen JY, et al. Clinical and CT Quantitative Features for Predicting Liver Metastases in Patients with Pancreatic Neuroendocrine Tumors: A Study with Prospective/External Validation. Acad Radiol. 2024. PMID: 38490841. doi:10.1016/j.acra.2024.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。